Recent content by jondoeuk

Triple Hair (Canada) began Phase 3 clinical trials for its Therapy-07 (THO7) topical in Vancouver, Canada, It contains minoxidil, finasteride and latanoprost. This product is already available for sale via prescription. However, in August, Triple Hair released an updated pipeline on its...

See my reply to coco_304

Pyrilutamide (KX-826) is sold directly to consumers as a cosmetic under the brand name Koshine ahead of completing approval. You can buy it here https://www.koshinemall.com?sca_ref=7290283.HUfjZVF7fCV5W

Per Kintor's latest pipeline page modification, pyrilutamide has entered the new drug application stage in China. If the application is successful with Chinese regulators (similar to the US FDA and EU EMA), the company expects that it will reach commercialisation in 2027. Pyrilutamide is a...

Kintor plans to initiate the phase IIb/III clinical trial of GT20029 for male androgenetic alopecia in China this year.

The randomised, double-blind, placebo-controlled phase two clinical trial was published. It entailed 180 Chinese adult males with androgenetic alopecia (Hamilton-Norwood IIIv-V). It lasted from April 2023 to April 2024. The subjects were randomised equally into six groups receiving GT20029 (0.5%...

GT20029 is an androgen receptor degrader (AR Degrader). It was developed using a proprietary Proteolysis Targeting Chimera (PROTAC) platform. This is the world's first topical androgen receptor (AR) compound (AR-PROTAC) to enter clinical trials. GT20029 degrades the AR protein via the E3...

0.5% BID (i.e. twice a day)

Pelage sent out an email: ''We are excited to provide a brief update on the clinical trials you signed up to hear about through our registry for androgenetic alopecia (pattern hair loss). Male study The AWAKEN clinical trial for men with androgenetic alopecia (Androgenetic Alopecia) is on track to launch this...

Currently, the company is actively advancing the marketing authorisation application for KX-826 in China.

It works https://www.hairlosstalk.com/interact/threads/pyrilutamide-kx-826-1-0-and-0-5.139682/

From Kintor Pharma: ''KT-215 is a topical MPC inhibitor under development by the Company. It activates hair follicle stem cells for Androgenetic Alopecia treatment. The mitochondrial pyruvate carrier (MPC) is located in the inner mitochondrial membrane. Studies have shown that when MPC is inhibited by drugs...

''In the treatment of androgenetic alopecia, the action mechanism of 17α-estradiol is to suppress 5α-reductase activity, which impedes the conversion of testosterone to the more potent metabolite DHT5,22,23. In addition, it inhibits 17β-dehydrogenase activity, resulting in a slowing of the...

Alfatradiol is used topically and could be cheaper.

What DHT blockers did you try?